BCV
NBIX icon

Banque Cantonale Vaudoise’s Neurocrine Biosciences NBIX Stock Holding History

Banque Cantonale Vaudoise’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-626
Closed -$89K – 908
2025
Q4 		$89K Buy
+626
New +$90.7K ﹤0.01% 643
2024
Q3 		– Sell
-740
Closed -$102K – 928
2024
Q2 		$102K Sell
740
-446
-38% -$61.2K ﹤0.01% 691
2024
Q1 		$164K Buy
1,186
+787
+197% +$107K 0.01% 596
2023
Q4 		$53K Sell
399
-1,295
-76% -$149K ﹤0.01% 792
2023
Q3 		$191K Sell
1,694
-2,705
-61% -$285K 0.01% 692
2023
Q2 		$415K Sell
4,399
-3,440
-44% -$336K 0.02% 527
2023
Q1 		$793K Buy
7,839
+3,400
+77% +$354K 0.04% 352
2022
Q4 		$530K Sell
4,439
-55
-1% -$6.44K 0.03% 434
2022
Q3 		$476K Buy
4,494
+64
+1% +$6.49K 0.03% 490
2022
Q2 		$432K Sell
4,430
-11,670
-72% -$1.08M 0.02% 529
2022
Q1 		$1.51M Buy
16,100
+11,600
+258% +$983K 0.07% 295
2021
Q4 		$383K Hold
4,500
– – 0.01% 656
2021
Q3 		$432K Sell
4,500
-619
-12% -$58.5K 0.02% 605
2021
Q2 		$498K Buy
5,119
+3,700
+261% +$355K 0.02% 590
2021
Q1 		$137K Buy
1,419
+30
+2% +$3.15K 0.01% 848
2020
Q4 		$133K Buy
1,389
+589
+74% +$56.9K 0.01% 806
2020
Q3 		$77K Sell
800
-1,500
-65% -$174K ﹤0.01% 865
2020
Q2 		$280K Buy
+2,300
New +$254K 0.02% 560
2020
Q1 		– Sell
-926
Closed -$100K – 935
2019
Q4 		$100K Buy
+926
New +$97K 0.01% 809

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Banque Cantonale Vaudoise's NBIX Position: Q1 2026 in Review

Banque Cantonale Vaudoise sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 626 shares — an estimated $89K sold.

Banque Cantonale Vaudoise first reported a position in NBIX in Q4 2019 and held it in 19 quarters. The position peaked at $1.51M in Q1 2022. 700 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Banque Cantonale Vaudoise reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 626 Neurocrine Biosciences shares in Q1 2026, an estimated $89K.
  • Banque Cantonale Vaudoise first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 19 quarters.
  • Banque Cantonale Vaudoise's Neurocrine Biosciences position peaked at $1.51M in Q1 2022.
  • 700 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q1 2026, filed 20 Apr 2026.